Prelude Therapeutics (PRLD) EBT Margin (2024 - 2026)

Prelude Therapeutics (PRLD) reported EBT Margin of 752.05% for Q1 2026, down 134.57% sequentially from 320.6% in Q4 2025.

Prelude Therapeutics (PRLD) EBT Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics (PRLD) has 3 years of EBT Margin data on file, last reported at 752.05% in Q1 2026.

For the quarter ending Q1 2026, EBT Margin changed N/A year-over-year to 752.05%; the trailing twelve-month figure through Mar 2026 stood at 891.23% (changed N/A YoY), and the FY2025 full-year result was 2606.84%, up 199825.0% from the prior year.
EBT Margin fell to 752.05% in Q1 2026, from 320.6% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 320.6% in Q4 2025 to a low of 2549.4% in Q3 2024.
A 3-year average of 1025.52% and a median of 752.05% in 2026 frame the typical range for EBT Margin.
Peak annual rise in EBT Margin reached 190294 bps in 2025, while the deepest fall reached 53847 bps in 2025.
Tracing PRLD's EBT Margin over 3 years: stood at 859.08% in 2024, then surged by 63 bps to 320.6% in 2025, then plunged by 135 bps to 752.05% in 2026.
Business Quant data shows PRLD's EBT Margin at 752.05% in Q1 2026, 320.6% in Q4 2025, and 646.46% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Prelude Therapeutics	324.30 Mn	179.71 Mn	-	-752.05%

Download Data